Verrica Pharmaceuticals Inc Stock News

Proceeds will fully retire debt facility from OrbiMed and fund company operations, thereby extending expected cash runway into mid-2027 Financing anchored by Caligan Partners LP and PBM Capital, along with new and existing investors; Caligan Partners entitled to designate a new member to Verrica's Board of Directors WEST CHESTER, Pa., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals In...

Verrica Pharmaceuticals Inc. ( VRCA ) Q3 2025 Earnings Call November 17, 2025 8:30 AM EST Company Participants Jayson Rieger - President, CEO & Director John Kirby - Interim Chief Financial Officer Conference Call Participants Kevin Gardner Stacy Ku - TD Cowen, Research Division Yuchen Ding - Jefferies LLC, Research Division John Todaro - Needham & Company, LLC, Research Division Brian Kemp Dol...

–   Company reports $14.3 million in revenue in Q3'25, consisting of $3.6 million in YCANTH ® revenue and $10.7 million of license and collaboration revenue –

– Exploratory Phase 2 analysis shows Verrica's novel oncolytic peptide, VP-315, reprograms the tumor microenvironment, increasing cytotoxic T-cell infiltration and reducing immunosuppressive T-regulatory cells – – Findings provide mechanistic immunologic support for clinical efficacy previously reported, including 97% calculated objective response rate and 51% complete histologic clearance rate...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Verrica Pharmaceuticals, Inc. (NASDAQ: VRCA) breached their fiduciary duties to shareholders. If you currently own Verrica stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court...

– EMA concludes that the primary endpoint and supportive secondary endpoints from prior successful Phase 3 studies conducted in the U.S. and Japan are adequate to support a filing for the approval of YCANTH ® in the EU and that no additional Phase 3 studies are required –

WEST CHESTER, Pa., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that it will be presenting both an oral presentation and a poster on VP-315, its oncolytic peptide for the treatment of basal cell carcinoma (BCC), at...

– Approval triggers $10 million cash milestone payment to Verrica – – YCANTH ® approval in Japan addresses significant unmet need of patients with molluscum – – Verrica maintains ownership of global rights to YCANTH for all indications in all territories outside of Japan – WEST CHESTER, Pa., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatolog...